curasan AG: Novel Bone Regeneration Material Approved for Sale in Europe
curasan AG has received European approval for a novel synthetic bone regeneration material.
Kleinostheim, Germany, March 30, 2011 --(PR.com)-- curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received European approval for a novel synthetic bone regeneration material.
Osseolive® is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation.
“With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate products,” stated Hans Dieter Rössler, CEO. “Osseolive® has been specifically designed for the treatment of large defects in combination with bone growth supporting substances, such as bone marrow aspirate, stem cells, and bone morphogenetic proteins (BMPs).”
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. Some of these various new developments are ready yet for market rollout. These biomaterials will be marketed globally by well-positioned contractual partners. Further products will follow until end of 2012.
www.curasan.com
Press Contact:
curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner@curasan.de
www.curasan.de
fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner@finanical-relations.de
###
Osseolive® is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation.
“With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate products,” stated Hans Dieter Rössler, CEO. “Osseolive® has been specifically designed for the treatment of large defects in combination with bone growth supporting substances, such as bone marrow aspirate, stem cells, and bone morphogenetic proteins (BMPs).”
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. Some of these various new developments are ready yet for market rollout. These biomaterials will be marketed globally by well-positioned contractual partners. Further products will follow until end of 2012.
www.curasan.com
Press Contact:
curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner@curasan.de
www.curasan.de
fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner@finanical-relations.de
###
Contact
curasan AG
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Contact
Categories